Loading...
Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir
Dolutegravir is a second generation integrase strand transfer inhibitor (INSTI) currently under review by the US FDA for marketing approval. Dolutegravir’s in vitro, protein adjusted 90% inhibitory concentration (IC(90)) for wild-type virus is 0.064 μg/ml, and it retains in vitro anti-HIV 1 activity...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2013
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3805712/ https://ncbi.nlm.nih.gov/pubmed/23824675 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40262-013-0093-2 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|